胰高血糖素受体
内体
细胞生物学
胰高血糖素
生物
葡萄糖稳态
信号转导
基因敲除
胰高血糖素样肽1受体
受体
细胞内
内分泌学
兴奋剂
内科学
生物化学
胰岛素
胰岛素抵抗
基因
医学
作者
Revathi Sekar,Karsten Motzler,Yun Kwon,Aaron Novikoff,Julia Jülg,Bahar Najafi,Surui Wang,Anna-Luisa Warnke,Susanne Seitz,Daniela Hass,Sofiya Gancheva,S. Kahl,Bin Yang,Brian Finan,Kathrin V. Schwarz,Juergen G. Okun,Michael Roden,Matthias Blüher,Timo D. Müller,Natalie Krahmer
出处
期刊:Cell Metabolism
[Cell Press]
日期:2022-10-14
卷期号:34 (11): 1824-1842.e9
被引量:14
标识
DOI:10.1016/j.cmet.2022.09.022
摘要
During mammalian energy homeostasis, the glucagon receptor (Gcgr) plays a key role in regulating both glucose and lipid metabolisms. However, the mechanisms by which these distinct signaling arms are differentially regulated remain poorly understood. Using a Cy5-glucagon agonist, we show that the endosomal protein Vps37a uncouples glucose production from lipid usage downstream of Gcgr signaling by altering intracellular receptor localization. Hepatocyte-specific knockdown of Vps37a causes an accumulation of Gcgr in endosomes, resulting in overactivation of the cAMP/PKA/p-Creb signaling pathway to gluconeogenesis without affecting β-oxidation. Shifting the receptor back to the plasma membrane rescues the differential signaling and highlights the importance of the spatiotemporal localization of Gcgr for its metabolic effects. Importantly, since Vps37a knockdown in animals fed with a high-fat diet leads to hyperglycemia, although its overexpression reduces blood glucose levels, these data reveal a contribution of endosomal signaling to metabolic diseases that could be exploited for treatments of type 2 diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI